A Phase 1, First-in-Man, Multicenter, Open-Label, Two Part Dose- Escalation and Cohort Expansion Study of Single-Agent GBR 1342 in Subjects With Previously Treated Multiple Myeloma

Trial Profile

A Phase 1, First-in-Man, Multicenter, Open-Label, Two Part Dose- Escalation and Cohort Expansion Study of Single-Agent GBR 1342 in Subjects With Previously Treated Multiple Myeloma

Recruiting
Phase of Trial: Phase I

Latest Information Update: 04 Jul 2018

At a glance

  • Drugs GBR 1342 (Primary)
  • Indications Multiple myeloma
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors Glenmark Pharmaceuticals Ltd
  • Most Recent Events

    • 05 Jun 2018 Study design was presented at the 54th Annual Meeting of the American Society of Clinical Oncology
    • 25 May 2018 According to a Glenmark Pharmaceuticals media release, data from this trial will be presented at the Annual Meeting of the American Society of Clinical Oncology (ASCO) (2018).
    • 06 Mar 2018 Planned primary completion date changed from 1 Mar 2018 to 1 Mar 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top